Infantile spasms are seizures manifesting within a spectrum of epileptic encephalopathies of infancy that often lead to cognitive impairment. Their current therapies, including adrenocorticotropic hormone (ACTH), high dose steroids, or vigabatrin, are not always effective and may be associated with serious side effects. Overactivation of the TORC1 complex of the mTOR pathway is implicated in the pathogenesis of certain genetic and acquired disorders that are linked with infantile spasms, like tuberous sclerosis. Here, we tested the therapeutic potential of rapamycin, a TORC1 inhibitor, as a potential treatment for infantile spasms in the multiple-hit rat model of ACTH-refractory symptomatic infantile spasms, which is not linked to tuberous sclerosis. Rapamycin or vehicle was given after spasms appeared. Their effects on spasms, other seizures, performance in Barnes maze, and expression of the phosphorylated S6 ribosomal protein (pS6: a TORC1 target) in the cortex, using immunofluorescence, were compared. Rapamycin suppressed spasms dosedependently and improved visuospatial learning, although it did not reduce the frequency of other emerging seizures. High-dose pulse rapamycin effected acute and sustained suppression of spasms and improved cognitive outcome, without significant side effects. Therapeutically effective rapamycin doses normalized the pS6 expression, which was increased in perilesional cortical regions of pups with spasms. These findings support that pathological overactivation of TORC1 may be implicated in the pathogenesis of infantile spasms, including those that are not linked to tuberous sclerosis. Furthermore, a high-dose, pulse rapamycin treatment is a promising, well tolerated and disease-modifying new therapy for infantile spasms, including those refractory to ACTH.
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Introduction
Infantile spasms (IS) appear in a spectrum of epileptic encephalopathies of infancy that often lead to cognitive impairment (Hrachovy and Frost, 2003; Pellock et al., 2010) . IS have distinct pharmacosensitivity, as they do not respond to most classical antiepileptic therapies. The current therapies for IS include adrenocorticotropic hormone (ACTH), high dose steroids or vigabatrin, but these are not always effective and can be associated with severe adverse effects (Chiron et al., 1991; Baram et al., 1996; Vigevano and Cilio, 1997; Mackay et al., 2004; Kossoff et al., 2009; Willmore et al., 2009) . Early cessation of spasms has been linked with better longterm developmental outcomes (Riikonen, 2001; Lux et al., 2004; Darke et al., 2010; Riikonen, 2010) . However, response to therapy and long-term outcomes can be worse in patients with symptomatic IS (SIS) that are due to underlying structural/metabolic etiologies (Riikonen, 1982; Lombroso, 1983; Riikonen, 2001; Hrachovy and Frost, 2003; Mackay et al., 2004; Engel, 2006; Berg et al., 2010; Chudomelova et al., 2010) . The etiologies of IS are multivariate, with 200 etiologies having been recorded (Hrachovy and Frost, 2003) , yet an interesting link exists with tuberous sclerosis (TSC), as a significant percentage of patients with TSC manifest IS (Curatolo et al., 2001; Chu-Shore et al., 2010; Chudomelova et al., 2010) . TSC is a genetic disorder attributed to loss of function mutations in TSC1 or TSC2 genes, which cancel their inhibitory control over mTORC1 (mammalian target of rapamycin (mTOR) complex 1) and, as a result, the activity of its downstream targets remains aberrantly increased, leading to excessive cellular proliferation and dysplastic cells (Crino, 2010 
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